Drug Type Antibody drug conjugate (ADC) |
Synonyms GenSci-139 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | China | 27 Apr 2025 | |
Colorectal Cancer | Preclinical | China | 27 Apr 2025 | |
Lung Cancer | Preclinical | China | 27 Apr 2025 | |
Ovarian Cancer | Preclinical | China | 27 Apr 2025 | |
Stomach Cancer | Preclinical | China | 27 Apr 2025 | |
Transitional Cell Carcinoma | Preclinical | China | 27 Apr 2025 |